Results from the phase 3 PARADIGM trial

Professor Takayuki Yoshino presented at the recent ASCO 2022 new data about the PARADIGM trial. He summerized us the main findings. (Panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first‐line treatment in patients with RAS wild‐type metastatic colorectal cancer)

Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials?

Professor Richard D. Kim presented a data about the long term follow-up of the KEYNOTE-651 study at the recent ASCO 2022 congress. We asked him about the new informations and also about the KEYNOTE-177 trial.